01 11Madopar
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 378
2018 Revenue in Millions : 351
Growth (%) : 8
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 402
2019 Revenue in Millions : 409
Growth (%) : -2
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 424
2020 Revenue in Millions : 383
Growth (%) : 9
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 414
2021 Revenue in Millions : 424
Growth (%) : -2
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 412
2022 Revenue in Millions : 414
Growth (%) : -6
Main Therapeutic Indication : Neurology
Currency : USD
2024 Revenue in Millions : 405
2023 Revenue in Millions : 412
Growth (%) : -2
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions : -6.70%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 295
2014 Revenue in Millions : 278
Growth (%) : -6%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 287
2015 Revenue in Millions : 272
Growth (%) : 5
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 354
2016 Revenue in Millions : 307
Growth (%) : 15
